AustCancer miffed by market reaction
25 November, 2002 by Pete YoungCancer vaccine developer Australian Cancer Technology is mystified and disappointed by negative share market reaction to positive news from human trials of its cancer vaccine, Pentrix.
CSL celebrates cervical cancer vaccine success
21 November, 2002 by Graeme O'NeillCancer research is all hard slog, a long journey of many small steps, punctuated all too rarely by a genuine leap forward -- like the one announced today by CSL and its partner, pharma giant Merck and Co.
Sirtex moves toward US target
21 November, 2002 by Melissa TrudingerSirtex Medical is on track to achieve its goal of rolling out its SIR-Spheres cancer treatment in ten US hospitals by the end of the year, according to CEO Colin Sutton, with the ninth centre at Emory University Hospital treating its first two patients last week.
UTS brings in American to head infectious disease institute
19 November, 2002 by Graeme O'NeillThe University of Technology, Sydney (UTS) has appointed eminent American parasitologist Prof Michael Wallach as director of its new Institute for the Biotechnology of Infectious Diseases.
Research grant to help crystallise malaria mystery
18 November, 2002 by Pete YoungEncouraging results are flowing for Australian researchers using computer graphics to find inhibitors of a protein that plays a pivotal role in the life cycle of the parasite that causes malaria.
Cancer treatment targeted by new QIMR agreement
13 November, 2002 by Pete YoungGene discovery and drug development company diaDexus has signed a deal with the Queensland Institute for Medical Research (QIMR) concerning a novel molecule with potential for treating cancers in both males and females.
Monash pain research nets UK licensing deal
08 November, 2002 by Melissa TrudingerA new approach to treating pain has been licensed to British company RiboTargets by Monash University in a deal brokered by Victorian technology commercialisation company Biocomm.
Panbio moves into DNA diagnostics
05 November, 2002 by Pete YoungMedical diagnostics company Panbio Ltd, which has built its business around traditional microbiology kits, is moving into the fast-growing field of DNA probe-based diagnostics.
Gradipore says at AGM it will change
01 November, 2002 by David BinningHaving been promised the world, impatient shareholders of Sydney-based separations company Gradipore were demanding answers at Thursday's company AGM at the Australian Stock Exchange.
Medica achieves funding target in placement
30 October, 2002 by Melissa TrudingerMedica Holdings has raised $3.25 million in a private placement to leading Australian institutional investors.
Metabolic teams with BresaGen to produce anti-obesity compound
30 October, 2002 by Graeme O'NeillMelbourne biotechnology company Metabolic Pharmaceuticals has engaged Adelaide biotech BresaGen to develop a scaleable production system for its promising anti-obesity compound AOD9604.
Sirtex gains European approval
23 October, 2002 by Pete YoungAnti-cancer company Sirtex Medical has been given the green light to begin marketing and sales of its lead product SIR-Spheres in the European Community.
Interview: Brain research resonates for BRI scientist
23 October, 2002 by Melissa TrudingerTucked away in the corner of the Austin and Repatriation Medical Centre campus in Melbourne suburb of Heidelberg is the Brain Research Institute (BRI), devoted to research into epilepsy and other neural disorders, as well as the function of the healthy brain.
Nobel Laureates to speak at cancer conference
18 October, 2002 by Graeme O'NeillThe 2003 Lorne Protein and Cancer Conferences have snared two of the biggest names in medical research as guest speakers next February: 2002 Nobel Laureates Prof Sir Sidney Brenner and Prof Robert Horovitz.
Children's cancer targeted by ARC grant
18 October, 2002 by Graeme O'NeillThe survival rate of children with childhood cancers has increased spectacularly since the early 1960s, from a bleak 10 per cent to around 75 per cent today. One notable exception to the trend is neuroblastoma, with a survival rate below 50 per cent.
